Gene therapy startup snags $30M A round

The San Francisco-based gene therapy startup Audentes Therapeutics has rounded up an impressive $30 million A round. OrbiMed Advisors led the round with 5AM Ventures and Versant Ventures joining in. The money is earmarked for the development of AT001 for X-linked Myotubular Myopathy and AT002 for Pompe disease. Both AT001 and AT002 are based on adeno-associated virus gene therapy technology. "Our focused, experienced team is committed to advancing the promising scientific approach of gene therapy and looks forward to collaborating closely with our patient, research and medical community partners in this process," says CEO Matthew Patterson. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.